-
1 Comment
ADMA Biologics, Inc is currently in a long term downtrend where the price is trading 26.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.7.
ADMA Biologics, Inc's total revenue rose by 36.8% to $14M since the same quarter in the previous year.
Its net income has increased by 99.9% to $-19K since the same quarter in the previous year.
Finally, its free cash flow fell by 34.0% to $-36M since the same quarter in the previous year.
Based on the above factors, ADMA Biologics, Inc gets an overall score of 3/5.
None
Here's how to backtest a trading strategy or backtest a portfolio for ADMA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
